Levi & Korsinsky Investigates Potential Securities Law Violations at Viatris Inc.
New York, NY – March 14, 2025
Levi & Korsinsky, a leading securities law firm, notifies investors that it has commenced an investigation of Viatris Inc. (NASDAQ: VTRS) concerning potential securities laws violations. The investigation follows the company’s press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results.
Fourth Quarter and Full Year 2024 Financial Results Miss Consensus Estimates
Viatris reported a net loss of $1.5 billion for the fourth quarter, significantly wider than the expected net income of $378.4 million. The company also reported full year revenue of $12.4 billion, missing the consensus estimate of $12.7 billion. These results raised concerns among investors and analysts, leading to a significant decline in the company’s stock price.
Investigation Details
Levi & Korsinsky is investigating whether Viatris and certain of its officers or directors violated securities laws by making false and/or misleading statements and/or failing to disclose material information to investors. The investigation focuses on whether the company and its executives provided false and/or misleading information to the market regarding its financial condition and prospects.
Impact on Individual Investors
If it is determined that Viatris and its executives violated securities laws, affected investors may be entitled to compensation. Investors who purchased Viatris securities between certain dates are encouraged to contact Levi & Korsinsky to discuss their options for recovering their losses.
- Investors with $50,000 or more in losses
- Institutional investors
- Shareholders who purchased Viatris securities between February 27, 2023, and February 27, 2025
Impact on the World
The investigation and potential securities law violations at Viatris could have far-reaching implications for the healthcare industry and the broader market. Viatris is a leading global healthcare company, and its financial performance affects not only its investors but also its customers, suppliers, and competitors. A finding of securities law violations could lead to increased scrutiny of other healthcare companies and potentially impact investor confidence in the industry as a whole.
Conclusion
Levi & Korsinsky’s investigation of potential securities law violations at Viatris is a significant development for the healthcare industry and the broader market. Affected investors are encouraged to contact the firm to discuss their options for recovering their losses. The outcome of this investigation could have far-reaching implications for Viatris and the healthcare industry as a whole.
Stay informed of the latest news and developments regarding Viatris by visiting the firm’s website: www.zlk.com/pslra-1/viatris-inc-loss-submission-form?id=4245&source=031425-viatris
